Articles from Kaléo

Base award supports late-stage development, regulatory approval activities, and initial procurement of Kaléo’s next-generation 2-PAM auto-injector for organophosphate and nerve agent poisoning

Two newly published papers underscore the need for increased awareness, caregiver education, and preparedness to help ensure timely use of epinephrine during severe allergic reactions

Glen Allen, VA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Kaléo today announced that it has entered into a confidential license agreement with Amgen Inc. Under the terms of the agreement, Amgen obtained a license to certain of Kaléo's patented technology on auto-injectors. This agreement reflects Kaléo's innovative contribution to drug-device technologies and longstanding leadership in advancing patient-centric auto-injector solutions. Financial and other terms of the agreement were not disclosed.

New campaign elevates real voices and delivers practical, easy-to-use resources to help people recognize and respond to allergic emergencies

Award-winning film series brings visibility to the lived experiences of children and families navigating life-threatening allergic reactions, supporting broader advocacy and education efforts

The patented Aerio™ platform was designed to meet the highest standards of device function and form from food allergies to modern medical countermeasures

Appointments support the Company’s continued focus on life-saving solutions, preparedness, and trusted drug delivery technology

Richmond, Virginia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Kaléo, a global leader in drug-delivery device technology and auto-injector innovation, today announced it received the Prototype Innovation award by the Medical CBRN Defense Consortium (MCDC) in recognition of its successful prototype development of the Rapid Opioid Countermeasure System (ROCS) (Naloxone HCl Injection, USP) antidote for ultra-potent weaponized opioids. This is the first time the MCDC has awarded a stand-out prototype innovation completed under the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense’s (JPEO-CBRND) Other Transaction Agreement (OTA) contracting vehicle.

Richmond, Virginia, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Kaléo, a global leader in drug-delivery device technology and auto-injector innovation, today announced it received the Prototype Innovation award by the Medical CBRN Defense Consortium (MCDC) in recognition of its successful prototype development of the Rapid Opioid Countermeasure System (ROCS) (Naloxone HCl Injection, USP) antidote for ultra-potent weaponized opioids. This is the first time the MCDC has awarded a stand-out prototype innovation completed under the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense’s (JPEO-CBRND) Other Transaction Agreement (OTA) contracting vehicle.

Richmond, Virginia, July 24, 2025 (GLOBE NEWSWIRE) -- Kaléo, a global leader in drug-delivery device technology and auto-injector innovation, today announced that AUVI-Q® (epinephrine injection, USP) was cleared for use as a part of Axiom Mission 4 that took flight on June 25, 2025, and returned on July 15, 2025. AUVI-Q was selected by Axiom Space to support Axiom Space crew members in the event of an allergic emergency.

Richmond, Virginia, May 15, 2025 (GLOBE NEWSWIRE) -- New findings from a retrospective analysis of U.S. commercial claims data indicate that patients prescribed AUVI-Q® (epinephrine injection, USP) experienced lower rates of inpatient hospitalization for anaphylaxis compared to patients prescribed other epinephrine auto-injectors (EAIs). The results are being presented during the ISPOR 2025 North America Conference, May 13–16, 2025, in Montreal, Quebec, Canada.

The Early Childhood Anaphylaxis Collaborative is rallying the nation’s early childcare centers to improve their preparedness for food allergic emergencies

Richmond, Virginia, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Kaléo, a fully integrated pharmaceutical company dedicated to inventing, manufacturing, and commercializing life-transforming products, today announced the appointment of Theresa Matkovits, Ph.D., as its new Chief Development Officer.

Richmond, Virginia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Kaléo, a privately-held U.S. pharmaceutical company has announced a redesign of the AUVI-Q® (epinephrine injection, USP) commercial team structure to increase in-office support for healthcare providers. AUVI-Q is a prescription medicine used to treat emergency allergic reactions, including anaphylaxis, in people who are at risk for or who have a history of serious allergic reactions. 

The full development contract with options totals $27.7 million

Contract valued at more than $39 million over five years

Richmond, VA, June 27, 2023 (GLOBE NEWSWIRE) -- Kaléo, a fully integrated pharmaceutical company dedicated to creating innovative healthcare solutions to protect and empower patients, today announced appointments at the C-suite and executive level to continue positioning Kaléo for growth in 2023 and beyond.

Richmond, Virginia, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Kaléo, a fully integrated pharmaceutical company dedicated to inventing, manufacturing, and commercializing life-transforming products, today announced the appointment of Major General Elder Granger, M.D., U.S. Army, (Ret) as an independent member of its Board of Managers.

Please replace the release dated March 2, 2022, with the following corrected version due to multiple revisions.